Postmarketing Experience
In addition to the events reported above, as with other drugs in this class,
the following events have been reported rarely during postmarketing experience
with Parvachol, regardless of causality assessment:
Musculoskeletal:
rhabdomyolysis, myopathy.
Nervous System:
Dysfunction of certain cranial nerves which includes alteration of taste,
impairment of extra-ocular movement, facial paresis, peripheral nerve palsy.
Hypersensitivity:
anaphylaxis, lupus erythematosus-like syndrome, polymyalgia rheumatica,
dermatomyositis, vasculitis, purpura, hemolytic anemia, positive Ana, esrincrease,
arthritis, arthralgia, asthenia, photosensitivity, chills, malaise, toxic
epidermal necrolysis, erythema multiforme, including Stevens-Johnson syndrome.
Gastrointestinal: pancreatitis, hepatitis, including chronic active hepatitis,
cholestatic jaundice, fatty change in liver, cirrhosis, fulminant hepatic
necrosis, hepatoma.
Dermatologic: A variety of skin changes (e.g., nodules, discoloration, dryness
of mucous membranes, changes to hair/nails).
Reproductive:
gynecomastia.
Laboratory abnormality:
Thyroid function abnormalities, Elevated alkaline phosphatase and bilirubin. |
